FDA, EU agree to review Biogen's MS drug Plegridy

07/22/2013 | Pharmaceutical Business Review Online · PMLive.com (U.K.)

The FDA and the European Medicines Agency have accepted Biogen Idec's marketing applications for Plegridy, or peginterferon beta-1a, a subcutaneous injectable formulation for the treatment of relapsing forms of multiple sclerosis. The applications included data from the late-stage ADVANCE trial.

View Full Article in:

Pharmaceutical Business Review Online · PMLive.com (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA